Abstract
Fumagillin is an active amebicide and anti-infective isolated from the fungus Aspergillus fumigatus. Since its characterization in 1951, fumagillin has been studied extensively for its anti-infective properties. Although fumagillin is not approved for systemic use in the USA, this compound has one of the highest efficacies for the treatment of microsporidial infections in HIV-positive patients. Fumagillin does exhibit some side effects that have deterred its acceptance as a viable treatment, but the current body of research on the synthesis of novel analogs of this molecule shows an exciting and promising revival of this drug as both an anti-infective and antiangiogenic agent.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Review
MeSH terms
-
Aminopeptidases / antagonists & inhibitors
-
Aminopeptidases / chemistry
-
Angiogenesis Inhibitors / pharmacology*
-
Animals
-
Anti-Infective Agents / pharmacology*
-
Cyclohexanes / adverse effects
-
Cyclohexanes / metabolism
-
Cyclohexanes / pharmacology*
-
Cyclohexanes / therapeutic use
-
Fatty Acids, Unsaturated / adverse effects
-
Fatty Acids, Unsaturated / pharmacology*
-
Fatty Acids, Unsaturated / therapeutic use
-
Glycoproteins / antagonists & inhibitors
-
Glycoproteins / chemistry
-
Humans
-
Methionyl Aminopeptidases
-
O-(Chloroacetylcarbamoyl)fumagillol
-
Sesquiterpenes / adverse effects
-
Sesquiterpenes / metabolism
-
Sesquiterpenes / pharmacology
-
Sesquiterpenes / therapeutic use
Substances
-
Angiogenesis Inhibitors
-
Anti-Infective Agents
-
Cyclohexanes
-
Fatty Acids, Unsaturated
-
Glycoproteins
-
Sesquiterpenes
-
fumagillin
-
Aminopeptidases
-
METAP2 protein, human
-
Methionyl Aminopeptidases
-
O-(Chloroacetylcarbamoyl)fumagillol